| Market Capitalization (Millions $) |
15 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-11 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Tc Biopharm Holdings Plc
TC Biopharm Holdings Plc is a biopharmaceutical company that focuses on the development of immunotherapy treatments for various types of cancer. The company utilizes its proprietary T-cell receptor (TCR) therapy platform to engineer T cells that can recognize and attack cancer cells. TC Biopharm aims to provide targeted and personalized medicine to improve patient outcomes.
The company's TCR therapies are designed to stimulate the body's immune system to recognize and destroy cancer cells. These therapies have the potential to treat a wide range of cancer types, including solid tumors. TC Biopharm's approach involves extracting a patient's T cells, modifying them in the lab to express specific TCRs that recognize cancer antigens, and then reintroducing these modified T cells back into the patient.
TC Biopharm has a strong pipeline of clinical stage programs, with ongoing trials in various cancer indications, including lung cancer, melanoma, and solid tumors. The company's goal is to bring innovative and effective immunotherapies to patients who are unresponsive to standard treatment options.
In addition to its clinical programs, TC Biopharm also collaborates with academic institutions and partners with pharmaceutical companies to expand its TCR therapy platform and explore new applications. The company is committed to advancing the field of immunotherapy and making a significant impact on cancer treatment.
Company Address: Maxim 1, 2 Parklands Way Motherwell 0
Company Phone Number: 141 433 7557 Stock Exchange / Ticker: NASDAQ TCBP
|
